Indian startup Pharmarack eyes VC funds for pharmacy software offer

Funding

Indian firm Pharmarack Technologies said it hopes to land $2 million in venture capital to fund development of an online order and inventory management system for pharmacies and distributors in India.

Industry publication VCCircle cited Pradyumn Singh, CEO of Pharmarack, as saying that existing investor Unicorn India Ventures and others are in late-stage talks on the funds.

“While the existing investors have agreed to put in a part of the targeted amount, we are also in talks with a few marquee venture capital firms. We expect to close the round by the end of June,” Singh told the publication.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

India's pharmacy and drug distribution network is highly fragmented with a noticeable absence of nationwide chain operations that makes tracking products and inventory management difficult.

Founder Singh and partners want to offer the software across players in the industry as a way to keep track in real-time via web and mobile versions, telling VCCircle that most companies in India’s pharma sector lack detailed reports on what happens to product after manufacturing--often leading to poor inventor management and uncertain manufacturing schedules.

The software is now in use in the Maharashtra state cities of Mumbai, Pune, Thane and Nashik; the company aims to be in 35 cities by the end of the year with a monthly cost for users set to be around INR4,000 ($69) a month.

- here's the story from VCCircle

Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.